DrugPatentWatch Database Preview
Cumberland Pharms Company Profile
» See Plans and Pricing
What is the competitive landscape for CUMBERLAND PHARMS, and what generic alternatives to CUMBERLAND PHARMS drugs are available?
CUMBERLAND PHARMS has seven approved drugs.
There are twenty-six US patents protecting CUMBERLAND PHARMS drugs.
There are one hundred and eighty-one patent family members on CUMBERLAND PHARMS drugs in thirty-eight countries and fifteen supplementary protection certificates in fourteen countries.
Summary for Cumberland Pharms
| International Patents: | 181 |
| US Patents: | 26 |
| Tradenames: | 8 |
| Ingredients: | 7 |
| NDAs: | 7 |
Drugs and US Patents for Cumberland Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cumberland Pharms | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | RX | Yes | Yes | 7,351,691 | Start Trial | Y | Y | Start Trial | ||
| Cumberland Pharms | REDITREX | methotrexate | SOLUTION;SUBCUTANEOUS | 210737-003 | Nov 27, 2019 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-001 | Jun 11, 2009 | DISCN | No | No | 6,727,286 | Start Trial | Y | Start Trial | |||
| Cumberland Pharms | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-001 | Sep 11, 2009 | DISCN | Yes | No | 6,858,584 | Start Trial | Y | Start Trial | |||
| Cumberland Pharms | CALDOLOR | ibuprofen | SOLUTION;INTRAVENOUS | 022348-003 | Jan 25, 2019 | RX | Yes | Yes | 8,735,452 | Start Trial | Start Trial | ||||
| Cumberland Pharms | VIBATIV | telavancin hydrochloride | POWDER;INTRAVENOUS | 022110-002 | Sep 11, 2009 | RX | Yes | Yes | 6,872,701 | Start Trial | Y | Start Trial | |||
| Cumberland Pharms | REDITREX | methotrexate | SOLUTION;SUBCUTANEOUS | 210737-001 | Nov 27, 2019 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Cumberland Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Cumberland Pharms | VAPRISOL | conivaptan hydrochloride | INJECTABLE;INTRAVENOUS | 021697-001 | Dec 29, 2005 | 5,723,606 | Start Trial |
| Cumberland Pharms | VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER | conivaptan hydrochloride | INJECTABLE;INTRAVENOUS | 021697-002 | Oct 8, 2008 | 5,723,606 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CUMBERLAND PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 200 mg/mL, 30 mL vials | ➤ Subscribe | 2012-04-04 |
International Patents for Cumberland Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2543009 | Start Trial |
| Japan | 4669478 | Start Trial |
| China | 1223378 | Start Trial |
| China | 102625656 | Start Trial |
| New Zealand | 566100 | Start Trial |
| Canada | 2867477 | Start Trial |
| Taiwan | I305209 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cumberland Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1292612 | 122011100062 | Germany | Start Trial | PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ HIERVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902 |
| 1292612 | 11C0051 | France | Start Trial | PRODUCT NAME: TELAVANCINE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902 |
| 1292612 | CA 2011 00033 | Denmark | Start Trial | PRODUCT NAME: TELAVANCIN, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER TELAVANCIN HYDROCHLORID |
| 1292612 | 132012902025885 | Italy | Start Trial | PRODUCT NAME: TELAVANCINA(VIBATIV); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/705/001-002, 20110902 |
| 1292612 | PA2012002 | Lithuania | Start Trial | PRODUCT NAME: TELAVANCINUM; REGISTRATION NO/DATE: EU/1/11/705/001, 2011 09 02 EU/1/11/705/002 20110902 |
| 1292612 | 2011C/045 | Belgium | Start Trial | PRODUCT NAME: VIBATIV - TELAVANCINE; AUTHORISATION NUMBER AND DATE: EU/1/11/705-001 20110902 |
| 1292612 | 36/2011 | Austria | Start Trial | PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ HIEVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
